+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Ophthalmoplegia Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • PDF Icon

    Report

  • 350 Pages
  • July 2025
  • Region: Global
  • Expert Market Research
  • ID: 6163106
The ophthalmoplegia market size was valued at USD 1.03 billion in 2024, driven by the increasing advancements in healthcare and pharmaceutical industry across the 7 major markets. The market is expected to grow at a CAGR of 8.30% during the forecast period of 2025-2034, with the value likely to reach USD 2.29 billion by 2034.

Ophthalmoplegia: Introduction

Ophthalmoplegia is the weakness of the eye muscles, affecting one or more than one of the six muscles holding the eye in place and controlling its movement. It can be further segmented into chronic progressive external ophthalmoplegia and internal ophthalmoplegia. People suffering from ophthalmoplegia may have blurred or double vision, and even misaligned eyes in some cases. It is mostly diagnosed through MRI or CT scans.

Ophthalmoplegia Market Analysis

The incidence of ophthalmoplegia is slightly higher in people affected with diabetes. Since the prevalence of diabetes is growing due to the changes in modern lifestyles and unhealthy dietary practices, the ophthalmoplegia market demand has also observed an upswing. Along with diabetes, patients affected by multiple sclerosis or Graves' disease are also at a risk of developing the condition.

With the rising preference for minimally invasive surgical interventions, silicone sling procedure is commonly performed as an ophthalmoplegia treatment. This procedure is used to treat drooping eyelids, a critical symptom of the disease. It is performed with the help of a Seiff silicone suspension and the silicone is guided in the muscle through a stab incision. This procedure offers multiple advantages like early recovery, less surgical time, and no multiple incisions when compared to other methods.

Apart from surgical interventions and drugs like tetracycline, corticosteroid treatment, and botulinum toxin, vitamins are also used quite frequently. However, adopting traditional Chinese medicine as a complementary and alternative method, acupuncture is also being investigated as a potential therapeutic method. With a vision to cater to a diverse set of patients, scientists are looking into various approaches, which are poised to boost the ophthalmoplegia market value in the forecast period.

Ophthalmoplegia Market Segmentation

“Ophthalmoplegia Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

  • External Ophthalmoplegia
  • Internuclear Opthalmoplegia

Market Breakup by Treatment Type

  • Surgery
  • Drug Treatment
  • Others

Market Breakup by End User

  • Hospital and Clinics
  • Ambulatory Clinics
  • Others

Market Breakup by Region

  • United States
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Japan

Ophthalmoplegia Market Overview

North America has been dominating the ophthalmoplegia market share owing to factors like a well-developed healthcare infrastructure and the increased presence of prominent pharmaceutical companies. In addition, companies have been expanding their product portfolios for better patient outcomes.

Europe is another major market with a high emphasis on offering better healthcare solutions to patients. With substantial geriatric population, the region may experience more ophthalmoplegia cases in upcoming years. Therefore, there has been significant focus on developing innovative and highly effective treatment alternatives. The rising technical advancements that incorporate artificial intelligence and machine learning into drug development are some of the critical trends shaping the market value in the region.

The Asia Pacific is projected to witness significant ophthalmoplegia market growth which can be attributed to rising healthcare investments from the native governments as well as foreign companies. Along with improving the healthcare infrastructure, several influential pharmaceutical companies are setting up new research labs and clinics to put the easily available resources in the area to use.

Ophthalmoplegia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • F. Hoffmann-La Roche Ltd
  • Bausch Health
  • Johnson & Johnson Services, Inc.
  • Medline Industries
  • Santen Pharmaceutical Co.
  • Novartis AG
  • Abbott
  • Essilor
  • Astellas Pharma Inc.
  • Enzon Pharmaceuticals
  • Amritt, Inc.
  • NIDEK CO.
  • Carl Zeiss AG
  • Santen Pharmaceutical Co.
  • Medline Industries
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ophthalmoplegia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ophthalmoplegia Epidemiology Analysis - 7MM
5.1 7MM Epidemiology Scenario Overview (2018-2034)
5.2 United States Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3 EU-4 and United Kingdom Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3.1 Germany Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3.2 France Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3.3 Italy Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3.4 Spain Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.3.5 United Kingdom Ophthalmoplegia Epidemiology Forecast (2018-2034)
5.4 Japan Ophthalmoplegia Epidemiology Forecast (2018-2034)
6 Ophthalmoplegia Market Overview - 7MM
6.1 Ophthalmoplegia Market Historical Value (2018-2024)
6.2 Ophthalmoplegia Market Forecast Value (2025-2034)
7 Ophthalmoplegia Market Landscape - 7MM
7.1 Ophthalmoplegia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ophthalmoplegia Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Treatment Type
8 Ophthalmoplegia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ophthalmoplegia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ophthalmoplegia Market Segmentation - 7MM
11.1 Ophthalmoplegia Market by Type
11.1.1 Market Overview
11.1.2 External Ophthalmoplegia
11.1.3 Internuclear Opthalmoplegia
11.2 Ophthalmoplegia Market by Treatment Type
11.2.1 Market Overview
11.2.2 Surgery
11.2.3 Drug Treatment
11.2.4 Others
11.3 Ophthalmoplegia Market by End User
11.3.1 Market Overview
11.3.2 Hospital and Clinics
11.3.3 Ambulatory Clinics
11.3.4 Others
11.4 Ophthalmoplegia Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Ophthalmoplegia Market
12.1 Ophthalmoplegia Market Historical Value (2018-2024)
12.2 Ophthalmoplegia Market Forecast Value (2025-2034)
12.3 Ophthalmoplegia Market by Disease Type
12.4 Ophthalmoplegia Market by Treatment Type
13 EU-4 and United Kingdom Ophthalmoplegia Market
13.1 Ophthalmoplegia Market Historical Value (2018-2024)
13.2 Ophthalmoplegia Market Forecast Value (2025-2034)
13.3 Germany Ophthalmoplegia Market Overview
13.3.1 Ophthalmoplegia Market by Disease Type
13.3.2 Ophthalmoplegia Market by Treatment Type
13.4 France Ophthalmoplegia Market Overview
13.4.1 Ophthalmoplegia Market by Disease Type
13.4.2 Ophthalmoplegia Market by Treatment Type
13.5 Italy Ophthalmoplegia Market Overview
13.5.1 Ophthalmoplegia Market by Disease Type
13.5.2 Ophthalmoplegia Market by Treatment Type
13.6 Spain Ophthalmoplegia Market Overview
13.6.1 Ophthalmoplegia Market by Disease Type
13.6.2 Ophthalmoplegia Market by Treatment Type
13.7 United Kingdom Ophthalmoplegia Market Overview
13.7.1 Ophthalmoplegia Market by Disease Type
13.7.2 Ophthalmoplegia Market by Treatment Type
14 Japan Ophthalmoplegia Market
14.1 Ophthalmoplegia Market Historical Value (2018-2024)
14.2 Ophthalmoplegia Market Forecast Value (2025-2034)
14.3 Ophthalmoplegia Market by Disease Type
14.4 Ophthalmoplegia Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 F. Hoffmann-La Roche Ltd
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bausch Health
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Johnson & Johnson Services, Inc.
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Medline Industries
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 Santen Pharmaceutical Co.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Novartis AG
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Abbott
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Essilor
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Astellas Pharma Inc.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Enzon Pharmaceuticals
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Amritt, Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 NIDEK CO.
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Carl Zeiss AG
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Santen Pharmaceutical Co.
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Ophthalmoplegia Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Bausch Health
  • Johnson & Johnson Services, Inc.
  • Medline Industries
  • Santen Pharmaceutical Co.
  • Novartis AG
  • Abbott
  • Essilor
  • Astellas Pharma Inc.
  • Enzon Pharmaceuticals
  • Amritt, Inc.
  • NIDEK CO.
  • Carl Zeiss AG
  • Santen Pharmaceutical Co.